|
||
|
||
ESCOZUL |
||
After nearly 25 years used in treatment of cancer, Escozul has proven to be affective. It is in use in Asia (Japan), Europe (Greece, Germany, Spain), South America and now Canada. It attacks cancer growth only. It also helps to prevent the formation of metastatic colonies in other parts of the human body. Because of its proven positive results, it is finally revolutionizing CANCER TREATMENT TODAY. It has become more and more in demand without the usual advertising hype accompanying discoveries. The disinterest of conventional Oncologists in alternative treatments is shocking. They are not utilizing available means to help cancer patients. Physicians may learn about such new discoveries as Escozul on the Internet. Only a fraction of physicians do so while even less translate such discoveries into successful treatments of their seriously ill patients. Case in point: After cancer surgery morphine is administered to relieve surgical wound pain. Yet morphine induces ANGIOGENESIS, which promotes cancer metastasis. The puffer (blow) fish venom TECTON is 1000 times more potent than morphine against nerve pain, WITHOUT SIDE EFFECTS. For those scoffing at ESCOSUL, the following should serve as an eye opener: The University of Alabama is undertaking research in venom use of a hairy type scorpion of the Arizona desert to treat brain cancer (called Gleoma). The medicinal part of the venom is called CLOROTOXIN and targets and destroys GLEOMA cells only, leaving healthy brain tissue intact. This cancer befalls 72,000 people per year in the United States. This information was aired on PBS on April 6, 2005 on the program "Nature", Venom Research. To order a copy of this program call 1-800-336-1917. The cost of a DVD is $29.95 US or $36.00 CDN. The order number is GWPYZ. After more than 2 decades of ESCOZUL use the knowledge is not widespread. One explanation may be that demand is constantly higher that supply. For more information contact www.escozulinformation.com.
|
||
|
||
Send mail to webmaster@echoworld.com
with
questions or comments about this web site.
|